Enveric Biosciences Receives Nasdaq Deficiency Letter
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Enveric Biosciences ( (ENVB) ) is now available.
On August 26, 2025, Enveric Biosciences received a deficiency letter from Nasdaq for not meeting the minimum stockholders’ equity requirement of $2,500,000, as their reported equity was $2,184,769 as of June 30, 2025. The company has until October 10, 2025, to submit a compliance plan to Nasdaq, which could grant them an extension to meet the requirement, ensuring their continued listing on the Nasdaq Capital Market.
The most recent analyst rating on (ENVB) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Enveric Biosciences stock, see the ENVB Stock Forecast page.
Spark’s Take on ENVB Stock
According to Spark, TipRanks’ AI Analyst, ENVB is a Underperform.
Enveric Biosciences faces significant financial difficulties, with no revenue and ongoing losses, which heavily impacts its overall score. The technical indicators suggest a bearish trend, adding to the negative outlook. The valuation component is challenging due to negative earnings, making the stock less attractive. Overall, the company’s financial instability is the most significant factor affecting its stock score.
To see Spark’s full report on ENVB stock, click here.
More about Enveric Biosciences
Average Trading Volume: 209,810
Technical Sentiment Signal: Sell
Current Market Cap: $4.09M
Find detailed analytics on ENVB stock on TipRanks’ Stock Analysis page.
